Chandan Jeena Sikho deal crosses ₹1.50 crore monthly run-rate
Key highlights
- Chandan’s Jeena Sikho partnership has crossed a monthly revenue run-rate of more than ₹1.50 crore.
- About 80% of Jeena Sikho partner locations are operational across 23 states and more than 100 cities.
- Chandan’s B2B revenue grew 106.5% year on year in Q2 FY27 and accounted for 36.7% of standalone revenue.
- Jeena Sikho subscribed to 18,00,000 of 44,50,000 warrants in Chandan’s October 2025 preferential issue.
powered by IRIS

Chandan’s exclusive five-year partnership with Jeena Sikho Lifecare Limited has crossed a ₹1.50 crore monthly revenue run-rate while about 80% of partner locations are operational across 23 states and more than 100 cities. The relationship is part of Chandan’s business-to-business, or B2B, segment, which grew 106.5% year on year in Q2 FY27.
Know Chandan Healthcare inside out
Results, valuation, peers and who's buying, in one view.
What does Chandan’s Jeena Sikho partnership cover?
Chandan is the exclusive diagnostics partner for all existing and upcoming Jeena Sikho Lifecare facilities under a five-year arrangement. Chandan establishes and operates company-owned laboratories inside or adjacent to partner hospitals and clinics, providing end-to-end pathology and radiology services for inpatient and outpatient departments.
The arrangement extends automatically to facilities that Jeena Sikho opens in the future. The partner network spans 23 states and more than 100 cities, while the disclosed monthly revenue run-rate of more than ₹1.50 crore gives a current measure of the relationship’s scale. Chandan says that monthly revenue continues to rise, but does not disclose cumulative revenue, a future run-rate target or the partnership’s share of B2B revenue.
The model differs from Chandan’s franchise channel, where franchisees collect pathology samples and route them to the nearest Chandan laboratory. A franchisee typically invests about ₹1 lakh in a computer, printer and premises fit-out, while Chandan says it makes no capital investment in those collection points. Jeena Sikho locations, by contrast, use Chandan-owned laboratories and include both pathology and radiology operations.
Jeena Sikho also subscribed to 18,00,000 warrants in Chandan’s preferential issue approved in October 2025. The full issue comprised 44,50,000 warrants. The presentation identifies the subscription but does not state the warrant conversion price, conversion schedule or use of proceeds.
How much of Chandan’s Jeena Sikho rollout is operational?
About 80% of Jeena Sikho partner locations are operational, and Chandan targets the balance for rollout over the coming months. The presentation does not disclose the total number of sites or the number still awaiting opening, although it describes the covered network as operating across 23 states and more than 100 cities.
The more than ₹1.50 crore monthly run-rate was achieved before the remaining roughly 20% of locations became operational. This means the disclosed revenue marker relates to a partially deployed partner network. Chandan has not provided a revenue projection for the completed rollout, so the eventual contribution cannot be calculated from the presentation.
Chandan’s wider clinical infrastructure includes 16 magnetic resonance imaging, or MRI, machines, 20 computed tomography, or CT, machines, 28 ultrasound machines and 35 digital X-ray machines. The company also reports 16 National Accreditation Board for Testing and Calibration Laboratories, or NABL, accredited laboratories, eight National Accreditation Board for Hospitals and Healthcare Providers, or NABH, accredited centres, and 30 Atomic Energy Regulatory Board, or AERB, licensed radiology centres.
Got a follow-up? Ask IRIS
Why did Chandan’s B2B revenue grow faster than other segments?
Chandan’s B2B revenue grew 106.5% year on year in Q2 FY27, exceeding growth of 23.8% in business-to-consumer, or B2C, retail diagnostics and 17.2% in business-to-government, or B2G, public-private partnership work. B2B represented 36.7% of standalone revenue, ahead of B2C at 34.5% and B2G at 28.8%.
Chandan’s B2B channel serves more than 230 hospitals, clinics, corporates, insurers, third-party administrators, or TPAs, and laboratories, alongside more than 200 institutional affiliations. Services include company-operated hospital laboratories, employee health programmes, pre-policy examinations, claims-related investigations, and specialised testing through central reference laboratories.
The Jeena Sikho relationship is one disclosed institutional partnership, but Chandan does not attribute the 106.5% B2B increase to individual clients. The presentation says B2B contracts generate recurring volumes and typically have receivable cycles of one to two months. The partnership’s ₹1.50 crore-plus monthly run-rate is therefore a specific relationship metric, whereas the B2B growth rate covers the entire institutional business.
How does the Jeena Sikho deal fit Chandan’s network strategy?
The Jeena Sikho arrangement adds hospital-and-clinic diagnostic volumes to Chandan’s B2B channel, which was its largest disclosed standalone revenue segment at 36.7% in Q2 FY27. Its company-owned laboratory format differs from the franchise model, which uses asset-light collection points to feed samples into nearby Chandan laboratories.
Chandan reported 23 Comprehensive Diagnostic Centres, 18 Diagnostic Centres, 25 standalone laboratories and more than 500 franchise collection centres. The retail network is supported by more than 40,000 referring doctors, more than 40 lakh Chandan Family loyalty-card members and more than 3 lakh users of the Chandan 24x7 application. These channels provide patient access separately from the partner-hospital laboratory model.
The B2G business operates under another contract structure. Chandan lists 14 10-year radiology public-private partnership projects across Punjab, Haryana and Assam, while its Uttarakhand government work has operated since 2021 across 14 districts. Management intends to keep B2G at no more than approximately 40% of the revenue mix.
Chandan’s franchise roadmap reported 235 locations on 31 March 2026, 264 on 30 June 2026 and more than 500 by September 2026. Management targets more than 1,000 franchise locations by the end of FY27 and 3,000 over the next two years. The remaining Jeena Sikho rollout is separately targeted for completion over the coming months.
Conclusion
Chandan has established a measurable recurring-revenue channel through its five-year Jeena Sikho partnership, with monthly revenue above ₹1.50 crore at roughly 80% operational rollout. The hospital-based, company-owned laboratory model distinguishes the arrangement from franchise collection points, while B2B growth of 106.5% in Q2 FY27 outpaced the 23.8% B2C and 17.2% B2G growth rates.
The next disclosed marker is the planned rollout of the remaining Jeena Sikho locations over the coming months. Management’s separate targets of more than 1,000 franchise locations by the end of FY27 and 3,000 over the next two years will also show how quickly Chandan expands its collection network alongside institutional laboratory operations.


